We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Intensive rituximab regimen in immune‐mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment.
- Authors
Barba, Christophe; Peyre, Marion; Galicier, Lionel; Cathebras, Pascal; Ranta, Dana; Malot, Sandrine; Veyradier, Agnès; Coppo, Paul
- Abstract
Intensive rituximab regimen in immune-mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment We focused on iTTP patients in clinical remission who failed to display improved ADAMTS13 activity following a standard treatment with rituximab.3 Patients were enrolled prospectively in our registry from January 2012 to July 2018 through the French Reference Center for Thrombotic Microangiopathies network (www.cnr-mat.fr). We report that an intensive rituximab regimen inspired by maintenance regimens of low-grade B-cell lymphomas allows improving ADAMTS13 activity in most cases (>75% of formerly unresponsive patients), with an acceptable safety profile. So far, only single cases previously supported the relevance of this strategy.10,11,12 Of interest, all three patients who did not respond to intensive therapy received a regimen consisting in a twice-a-year infusion of rituximab instead of the two- to three-month infusion regimen typically offered to the other patients.
- Subjects
RITUXIMAB; THROMBOTIC thrombocytopenic purpura; IDIOPATHIC thrombocytopenic purpura; INSTITUTIONAL review boards
- Publication
British Journal of Haematology, 2021, Vol 192, Issue 1, pe21
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.17170